Table 3. Alterations in the levels of crystallin transcripts in diabetic retinopathy and the reversal of their levels by RAGE inhibitor and p38 MAPK inhibitor.
| |
|
Fold change* |
Fold change* |
Fold change* |
|---|---|---|---|---|
| Gene symbol | Gene name | D vs N | D + mRAGE-Fc vs N | D + PHA666859 vs N |
| Crybb2 |
Crystallin, Beta B2 |
19.8 |
3.6 |
2.4 |
| Cryba1 |
Crystallin, Beta A1 |
19.3 |
3.7 |
1.9 |
| Cryba4 |
Crystallin, Beta A4 |
18.3 |
3.8 |
2.4 |
| Crygs |
Crystallin, Gamma S |
18.2 |
3.9 |
2.5 |
| Cryaa |
Crystallin, Alpha A |
17.9 |
3.5 |
2.4 |
| Cryba2 |
Crystallin, Beta A2 |
16.4 |
3.4 |
2.1 |
| Crybb1 |
Crystallin, Beta B1 |
15.1 |
3.9 |
2.8 |
| Crybb3 |
Crystallin, Beta B3 |
9.2 |
3.2 |
2.5 |
| Cryab |
Crystallin, Alpha B |
6.6 |
3.6 |
1.9 |
| Crygb |
Crystallin, Gamma B |
4.5 |
3.2 |
2.2 |
| Crygd |
Crystallin, Gamma D |
3.9 |
2.6 |
2.3 |
| Crygc |
Crystallin, Gamma C |
2.4 |
1.7 |
1.6 |
| Crygn | Crystallin, Gamma N | 1.6 | 1.5 | 1.2 |
*D=diabetic control, n=nondiabetic control, D+mRAGE-Fc=diabetic plus murine RAGE-Fc fusion protein, D+PHA666859=diabetic plus p38 MAPK inhibitor PHA666859.